AI-Powered Drug Development Enters Clinical Boom Phase, Industry Set for Breakout in 2026

　　【Pharmaceutical Network Industry DynamicsIn recent years, AI has demonstrated value in shortening cycles and reducing costs in target discovery and molecular design in the pharmaceutical industry. As a result, an increasing number of pharmaceutical companies worldwide have begun to apply AI throughout clinical development and manufacturing processes, leading to a growing improvement in the success rate and efficiency of new drug research and development.
 

According to reports, since March 2026, at least four drugs developed based on AI pharmaceutical technology platforms have achieved milestone progress in clinical stages in China. These cover multiple cutting-edge fields such as RNA small molecules, AI-driven PHD inhibitors, and AI-assisted protein design.
 

On March 9, Akeso's new tri-specific antibody drug AK150 (ILT2/ILT4/CSF1R tri-specific antibody) received NMPA clinical trial implied permission for the treatment of advanced malignant solid tumors. AK150 is a tri-specific antibody targeting ILT2/ILT4/CSF1R developed by the company based on its AI pharmaceutical R&D technology platform and Tetrabody multi-antibody technology platform.
 

AK150 can simultaneously target ILT2, ILT4, and CSF1R, achieving synergistic anti-tumor effects, with the ability to modulate both innate and adaptive immune systems.
 

On March 9, Shanghai Henlius Biotech, Inc. announced that the IND application for HLX3901, an innovative molecule developed based on its self-developed T-cell engager (TCE) platform, has been approved by the National Medical Products Administration (NMPA) for the treatment of advanced or metastatic solid tumors.
 

HLX3901 is a quadruple-specific antibody drug with independent intellectual property rights, which is expected to bring a breakthrough immunotherapy solution for refractory tumors in clinical settings, such as small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NEC).
 

On March 6, Insilico Medicine announced that the first subject has been successfully enrolled and dosed in the Phase I clinical trial of ISM4808, an innovative drug for anemia in chronic kidney disease (CKD), which was previously licensed to TaiGen Biomedical. This trial is driven by AI as a PHD inhibitor.
 

The phase I clinical trial launched this time is a randomized, double-blind, placebo-controlled study, including single ascending dose (SAD) and multiple ascending dose (MAD) parts, aiming to evaluate the safety, tolerability, and pharmacokinetic characteristics of ISM4808 in healthy adults.
 

On March 2, ReviR Therapeutics (ReviR), an incubated company of XtalPi, announced that the first subject has been dosed in its small molecule drug pipeline RTX-117. This drug is the first candidate to enter clinical trials from a series of in-depth collaborations between XtalPi and ReviR, combining XtalPi's AI+RobotThe drug discovery platform and ReviR’s deep understanding of RNA biology were collaboratively discovered, designed, and optimized.
 

Data shows that RTX-117 is a Class I innovative drug pipeline in China specifically targeting Charcot-Marie-Tooth disease (CMT). Developed with the assistance of XtalPi's AI drug discovery platform, it has received dual IND approvals in both China and the U.S. for CMT and obtained clinical approval in China for Vanishing White Matter disease (VWM).
 

　　……
 

Overall, the recent completion of first patient dosing or entry into clinical stages for multiple AI-driven drugs marks the accelerated transition of AI pharmaceuticals development from a technological concept to a phase of clinical efficacy validation. In the future, leading companies with closed-loop technical capabilities, robust clinical pipeline data, and clear commercialization pathways will gain more market opportunities. However, industry reshuffling and differentiation are also expected to accelerate.
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.